CN104788337B - The synthetic method of imide analog compounds - Google Patents
The synthetic method of imide analog compounds Download PDFInfo
- Publication number
- CN104788337B CN104788337B CN201510101942.3A CN201510101942A CN104788337B CN 104788337 B CN104788337 B CN 104788337B CN 201510101942 A CN201510101942 A CN 201510101942A CN 104788337 B CN104788337 B CN 104788337B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- auxiliary agent
- substituent group
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The present invention relates to the synthetic method of a kind of imide analog compounds; described method promotes efficiently synthesizing of imide analog compounds with the catalyst system and catalyzing of FeCl2/ auxiliary agent; and by experiment of single factor means, the best of breed of component is optimized and obtains optimal Complex catalyst system; this preparation technology has opened up the preparation method of imide compound; and reaction yield is high, there is wide scale application prospect and market potential is worth.
Description
Technical field
The application is filing date " on 04 10th, 2014 ", and Application No. " 201410142432.6 ", patent name is
The divisional application of " synthetic method of a kind of imide analog compounds ".
Background technology
At present, acid imide structure is widely present in many to be had among bioactive drug molecule, and in reality
Pharmaceutical synthesis field in receive significant attention, such as, pecilocin, aniracetam and many comprise the natural product of heterocyclic compound
The synthesis of thing.
It is known that it is the most traditional synthesis strategy that acyl chlorides is used for constructing imide compound as acylating reagent, so
And the acyl chlorides reagent involved by this kind of method has many shortcoming such as unstability, corrosivity.In addition, by c h bond and N-H
Direct oxidation coupling between key is also the method that prior art is commonly used for the structure of C-N key, the NH nucleophilic that it mainly uses
Reagent has aminated compounds or specific amide (such as picolinamide or primary amide etc.), and example is as follows:
(" the EfficientDiastereoselectiveIntermolecularRhodium-such as LiangChungen
CatalyzedC-HAmination ", Angew.Chem.Int.Ed., 2006,45,4641-4644) report a kind of rhodium catalysis
C-H aminating reaction, its use sulfimide amide compound be nitrene precursor and containing c h bond substrate as limit component,
For the intramolecular C-H aminating reaction of rhodium catalysis, reaction equation is as follows:
(" the HighlyEfficientRuthenium (II) such as PhilipWaiHongChan
PhorphyrinCatalyzedAmidationofAldehydes”,Angew.Chem.Int.Ed.,2008,47,1138-
1140) report a kind of with PhI=NTs for nitrogen source, under the catalysis of ruthenium-porphyrin complex, realize the amidation process of C-H, its
Reaction equation is as follows:
(" the SynthesisofImidesbyPalladium-CatalyzedC-H such as BianYong-Jun
FunctionalizationofAldehydeswithSecondaryAmides”,Chem.Eur.J.2013,19,
1129-1133) reporting a kind of aldehyde compound is raw material with N-substituted N-aromatic ring-2-Methanamide, in palladium catalyst effect
The method of lower synthesizing secondary imide compound, its reaction equation is as follows:
(" the HighlyEfficientCopper-CatalyzedAmidationofAldehydesbyC-such as WangLong
HActivation ", Chem.Eur.J.2008,14,10722-10726) disclose a kind of aldehydes of copper catalysis in the presence of NBS
The amidation process of compound, the method is simple, practical and economy is strong, and its reaction equation is as follows:
But, above-mentioned prior art is still not able to meet current medical intermediate, the synthesis of chemical intermediate and research and development,
Its mainly due to: 1, the product yield of prior art is the most not high enough；2, catalyst relates generally to noble metal or the network of costliness
Compound, hence it is evident that add production cost.The defect that the present inventor exists for prior art, it is intended to by Design Theory and experiment
Research and explore a kind of practical, novel preparation process of imide compound that reaction yield is high, thus fully satisfiedization
The Production requirement of work medicine and other fields.
Summary of the invention
In order to overcome many defects as indicated above, this is conducted in-depth research by the present inventor, a large amount of having paid
After creative work, thus develop the novel preparation process of a kind of imide compound, and then complete the present invention.
Specifically, technical scheme and content relate to the synthetic method of a kind of formula III compound, described side
Method comprises the steps: to add formula I compound and FeCl in reactor2, stir and be passed through nitrogen and maintain nitrogen atmosphere, so
Backward system adds solvent toluene, adds formula II compound, TBHP (tert-butyl hydroperoxide) and auxiliary agent under stirring, continue
Continuous logical
Sealing after being passed through nitrogen, temperature reaction, addition shrend is gone out after completion of the reaction, ether extracts, and merges warp after organic facies
Anhydrous sodium sulfate is dried, filter, be concentrated in vacuo after, residue by silicagel column chromatogram purification, i.e. can get formula III compound:
Wherein:
R1 is with substituent group or unsubstituted C1-C6 alkyl, with substituent group or unsubstituted phenyl；
R2, R3 are each independently with substituent group or unsubstituted C1-C6 alkyl, with substituent group or unsubstituted benzene
Base or benzyl；
Described substituent group in R1-R3 is C1-C6 alkyl, C1-C6 alkoxy or halogen.
In the described synthetic method of the present invention, described halogen is fluorine, chlorine, bromine or iodine atom.
In the described synthetic method of the present invention, described C1-C6 alkyl refers to the alkyl with 1-6 carbon atom, and it can
For straight or branched, can be the most such as methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, sec-butyl, isobutyl group,
The tert-butyl group, n-pentyl, isopentyl, n-hexyl etc..
In the described synthetic method of the present invention, described C1-C6 alkoxyl refers to the base that C1-C6 alkyl is connected with oxygen atom
Group.
In the described synthetic method of the present invention, described auxiliary agent is 2-dicyclohexylphosphontetrafluoroborate-2', 4', 6'-tri isopropyl biphenyl
(Xphos), 1,10-o-phenanthroline and I2O5Mixture, wherein 2-dicyclohexyl phosphorus-2', 4', 6'-tri isopropyl biphenyl, 1,
10-phenanthroline and I2O5Mass ratio be 1:0.2-0.5:0.1-0.3, preferably 1:0.4:0.2.
In the described synthetic method of the present invention, described formula I compound and FeCl2Mol ratio be 1:0.02-0.1,
Can be such as 1:0.02,1:0.03,1:0.04,1:0.05,1:0.06,1:0.07,1:0.08,1:0.09 or 1:0.1, be preferably
1:0.04-0.07。
In the described synthetic method of the present invention, described formula I compound is 1:2-with the mol ratio of formula II compound
5, can be 1:2,1:2.5,1:3,1:3.5,1:4,1:4.5 or 1:5, preferably 1:2.5-4 in non-limiting manner.
In the described synthetic method of the present invention, described formula I compound is 1:2-3 with the mol ratio of TBHP, such as may be used
For 1:2,1:2.1,1:2.2,1:2.3,1:2.4,1:2.5,1:2.6,1:2.7,1:2.8,1:2.9 or 1:3, preferably 1:2.2-
2.5。
In the described synthetic method of the present invention, the molal volume of described formula I compound and toluene is than for 1:5-8mol/
L, i.e. every 1mol formula I compound uses 5-8L toluene, can be in non-limiting manner 1:5mol/L, 1:5.5mol/L, 1:6mol/L,
1:6.5mol/L, 1:7mol/L, 1:7.5mol/L or 1:8mol/L, preferably 1:5.5-6.5mol/L.
In the described synthetic method of the present invention, the ratio of described formula I compound in mol and auxiliary agent in gram
For 1:8-12mol/g, i.e. every 1mol formula I compound uses 8-12g auxiliary agent, can be 1:8mol/g, 1:9mol/ in non-limiting manner
G, 1:10mol/g, 1:11mol/g or 1:12mol/g.
In the described synthetic method of the present invention, the response time is without particular limitation, such as, can be 10-14h, indefiniteness
Ground can be 10h, 11h, 12h, 13h or 14h.
In the described synthetic method of the present invention, reaction temperature is 45-55 DEG C, such as, can be 45 DEG C, 50 DEG C or 55 DEG C.
In the described synthetic method of the present invention, described silica gel chromatography can use any silicon as known in the art
Glue column chromatography, such as, use the silica gel of 200-400 mesh, and eluent is the mixture of normal propyl alcohol and petroleum ether, wherein normal propyl alcohol, stone
The volume ratio of oil ether is 1:1.5.Unless otherwise prescribed, the operation of the silica gel chromatography in all embodiments below is and makes
It is that volume ratio is the normal propyl alcohol of 1:1.5 and the mixture of petroleum ether is purified behaviour with the silica gel of 200-400 mesh, eluent
Make.
Compared with prior art, the invention have the benefit that
1, FeCl is used first2The catalyst system and catalyzing of/auxiliary agent, it is achieved that imidizate is prepared in amide and aldehyde compound reaction
Compound, and reaction yield is greatly improved.
2, have studied the impact of adjuvant component this factor of kind, filtered out the best of breed of adjuvant component, effectively assisted
Reactivity worth is improved with catalyst.
Detailed description of the invention
Below by specific embodiment, the present invention is described in detail, but the purposes of these exemplary embodiments and
Purpose is only used for enumerating the present invention, and not the real protection scope to the present invention constitutes any type of any restriction, more non-general
Protection scope of the present invention is confined to this.
Embodiment 1
1mol formula I compound and 0.06mol FeCl is added in reactor2, stir and be passed through nitrogen and maintain blanket of nitrogen
Enclose, in system, then add 6L solvent toluene, under stirring, add 3mol formula II compound, 2.2molTBHP and mass ratio
For the 2-dicyclohexylphosphontetrafluoroborate-2' of 1:0.4:0.2,4', 6'-tri isopropyl biphenyl (Xphos), 1,10-o-phenanthroline and I2O5Help
Agent composition (gross mass is 10g), seals after continuing all to enter nitrogen, and heat up 50 DEG C of reaction 14h, adds shrend after completion of the reaction
Go out, use ether to extract, merge after organic facies after being dried through anhydrous sodium sulfate, filtering, be concentrated in vacuo, residue by silicagel column color
Spectrum purification, i.e. can get formula III compound, and yield is 93.8%, and purity is 98.9% (HPLC).
1HNMR(400MHz,CDCl3)δ=7.62-7.49(m,5H),3.21(s,3H),2.33(s,3H)；
MS[M+H]+:177.07。
Embodiment 2
1mol formula I compound and 0.04mol FeCl is added in reactor2, stir and be passed through nitrogen and maintain blanket of nitrogen
Enclose, in system, then add 5.5L solvent toluene, under stirring, add 2.5mol formula II compound, 2.5molTBHP and matter
Amount is than the 2-dicyclohexylphosphontetrafluoroborate-2' for 1:0.4:0.2,4', 6'-tri isopropyl biphenyl (Xphos), 1,10-o-phenanthroline and I2O5
Agent mixture (gross mass is 12g), continue all to enter after nitrogen and seal, heats up 55 DEG C and react 12h, add after completion of the reaction
Shrend is gone out, is used ether to extract, and merges after organic facies after being dried through anhydrous sodium sulfate, filtering, be concentrated in vacuo, residue over silica gel
Column chromatography purification, i.e. can get formula III compound, and yield is 94.6%, and purity is 98.7% (HPLC).
1HNMR(400MHz,CDCl3)δ=7.61-7.59(m,2H),7.36-7.29(m,3H),7.07-7.04(m,2H),
6.82(m,2H),3.71(s,3H),2.38(s,3H)；
MS[M+H]+:269.10。
Embodiment 3
1mol formula I compound and 0.05mol FeCl is added in reactor2, stir and be passed through nitrogen and maintain blanket of nitrogen
Enclose, in system, then add 6.5L solvent toluene, under stirring, add 4mol formula II compound, 2.4molTBHP and quality
Than the 2-dicyclohexylphosphontetrafluoroborate-2' for 1:0.4:0.2,4', 6'-tri isopropyl biphenyl (Xphos), 1,10-o-phenanthroline and I2O5's
Agent mixture (gross mass is 8g), seals after continuing all to enter nitrogen, and heat up 50 DEG C of reaction 13h, adds water after completion of the reaction
Cancellation, use ether extraction, merge after organic facies after being dried through anhydrous sodium sulfate, filtering, be concentrated in vacuo, residue by silicagel column
Chromatogram purification, i.e. can get formula III compound, and yield is 94.1%, and purity is 98.8% (HPLC).
1HNMR(400MHz,CDCl3)δ=7.62(d,J=8.0Hz,2H),7.41-7.22(m,6H),7.16(d,J=
8.0Hz,2H),2.44(s,3H)；
MS[M+H]+:240.10。
Embodiment 4
1mol formula I compound and 0.07mol FeCl is added in reactor2, stir and be passed through nitrogen and maintain blanket of nitrogen
Enclose, in system, then add 6L solvent toluene, under stirring, add 3.5mol formula II compound, 2.3molTBHP and quality
Than the 2-dicyclohexylphosphontetrafluoroborate-2' for 1:0.4:0.2,4', 6'-tri isopropyl biphenyl (Xphos), 1,10-o-phenanthroline and I2O5's
Agent mixture (gross mass is 10g), seals after continuing all to enter nitrogen, and heat up 55 DEG C of reaction 11h, adds water after completion of the reaction
Cancellation, use ether extraction, merge after organic facies after being dried through anhydrous sodium sulfate, filtering, be concentrated in vacuo, residue by silicagel column
Chromatogram purification, i.e. can get formula III compound, and yield is 94.5%, and purity is 98.4% (HPLC).
1HNMR(400MHz,CDCl3)δ=7.45-7.43(m,1H),7.38-7.36(m,1H),7.26-7.12(m,7H),
4.95(s,2H),2.31(s,3H)；
MS[M+H]+:271.10。
Embodiment 5-8
Except by FeCl2Replace with outside following component, in the way of identical with embodiment 1-4, implement embodiment respectively
5-8, component is as shown in table 1 below with the corresponding relation of experimental result.
Table 1
"--" represent without.
From embodiment 1-4 and the result of table 1, the present inventor is by experimental studies have found that: at this catalyst/auxiliary agent body
The catalyst that can produce optimum catalytic performance in system is FeCl2, and table when other similar iron salt compounds are catalyst
Reveal the low yield differed greatly or do not react.Which demonstrating catalyst type is the key factor affecting reaction process, secondly
Obvious correlation is there is likely to be between catalyst and auxiliary agent.
Embodiment 9-12
Except by the 2-dicyclohexylphosphontetrafluoroborate-2' in auxiliary agent, 4', 6'-tri isopropyl biphenyl (Xphos) replaces with following component
Outward, implementing embodiment 9-12 in the way of identical with embodiment 1-4 respectively, component is as follows with the corresponding relation of experimental result
Shown in table 2.
Table 2
Embodiment 13-16
Except by 1 in auxiliary agent, 10-o-phenanthroline replaces with outside following component, in the way of identical with embodiment 1-4
Implementing embodiment 13-16 respectively, component is as shown in table 3 below with the corresponding relation of experimental result.
Table 3
Embodiment 17-20
Except being not added with I in auxiliary agent2O5Outward, in the way of identical with embodiment 1-4, embodiment 17-20, group are implemented respectively
Divide as shown in table 4 below with the corresponding relation of experimental result.
Table 4
"--" represent without.
From embodiment 1-4 and the result of table 2-table 4, between each component of auxiliary agent, there is close association and synergism, logical
Cross and study component 1 and the kind of component 2 and optimized choice goes out 2-dicyclohexylphosphontetrafluoroborate-2', 4', 6'-tri isopropyl biphenyl (Xphos)
With 1,10-o-phenanthroline, demonstrated component 3 by research component 3 indispensable in auxiliary agent, it can affect whole system
Reactivity worth.The method that the present inventor is combined with laboratory facilities by theoretical knowledge, not only constructs multiple with iron salt catalyst
The novel auxiliary system joined, but also component each to auxiliary agent has carried out suitable selection, achieves the technique effect of excellence simultaneously.
In sum, the present inventor passes through substantial amounts of creative work, have developed the novel system of a kind of imide compound
Standby technique, it is with FeCl2The catalyst system and catalyzing of/auxiliary agent and achieve and promote efficiently synthesizing of imide compound, and pass through Dan Yin
The best of breed of component is optimized and obtains optimal catalyst system and catalyzing by element laboratory facilities, and it is sub-that this preparation technology has opened up acyl
The preparation method of amines, and there is certain prospects for commercial application and market potential.
Should be appreciated that the purposes of these embodiments is merely to illustrate the present invention and is not intended to limit the protection model of the present invention
Enclose.Additionally, it will also be appreciated that after the technology contents having read the present invention, the present invention can be made respectively by those skilled in the art
Planting change, amendment and/or modification, all these equivalent form of value falls within the guarantor that the application appended claims is limited equally
Within the scope of protecting.
Claims (1)
1. a synthetic method for formula (III) compound, described method comprises the steps: that adding formula (I) in reactor changes
Compound and FeCl2, stir and be passed through nitrogen and maintain nitrogen atmosphere, in system, then add solvent toluene, add under stirring
Formula (II) compound, TBHP and auxiliary agent, seal after continuing to be passed through nitrogen, temperature reaction, add after completion of the reaction shrend go out, ether
Extraction, merges after organic facies after being dried through anhydrous sodium sulfate, filtering, be concentrated in vacuo, residue by silicagel column chromatogram purification,
Obtain formula (III) compound:
Wherein:
R1 is with substituent group or unsubstituted C1-C6 alkyl, with substituent group or unsubstituted phenyl；
R2, R3 be each independently with substituent group or unsubstituted C1-C6 alkyl, with substituent group or unsubstituted phenyl or
Benzyl；
Described substituent group in R1-R3 is C1-C6 alkyl, C1-C6 alkoxy or halogen；
Described auxiliary agent is 2-dicyclohexylphosphontetrafluoroborate-2', 4', 6'-tri isopropyl biphenyl, 1,10-o-phenanthroline and I2O5Mixture；
2-dicyclohexylphosphontetrafluoroborate-2' in described auxiliary agent, 4', 6'-tri isopropyl biphenyl, 1,10-o-phenanthroline and I2O5Mass ratio be 1:
0.4:0.2；Described formula (I) compound and FeCl2Mol ratio be 1:0.06；Described formula (I) compound and formula (II) compound
Mol ratio be 1:3；Described formula (I) compound is 1:2.2 with the mol ratio of TBHP；Described formula (I) compound rubs with toluene
Your volume ratio is 1:6mol/L；Described formula (I) compound in mol is 1:10mol/g with the ratio of auxiliary agent in gram；Instead
It is 14h between Ying Shi；Reaction temperature is 50 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510101942.3A CN104788337B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510101942.3A CN104788337B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
| CN201410142432.6A CN103880699B (en) | 2014-04-10 | 2014-04-10 | Method for synthesizing imides compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410142432.6A Division CN103880699B (en) | 2014-04-10 | 2014-04-10 | Method for synthesizing imides compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104788337A CN104788337A (en) | 2015-07-22 |
| CN104788337B true CN104788337B (en) | 2016-09-28 |
Family
ID=50949869
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510101921.1A Active CN104744290B (en) | 2014-04-10 | 2014-04-10 | A kind of synthetic method of imide analog compounds |
| CN201510101942.3A Active CN104788337B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
| CN201510101939.1A Active CN104788335B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
| CN201510101941.9A Active CN104788336B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
| CN201410142432.6A Active CN103880699B (en) | 2014-04-10 | 2014-04-10 | Method for synthesizing imides compounds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510101921.1A Active CN104744290B (en) | 2014-04-10 | 2014-04-10 | A kind of synthetic method of imide analog compounds |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510101939.1A Active CN104788335B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
| CN201510101941.9A Active CN104788336B (en) | 2014-04-10 | 2014-04-10 | The synthetic method of imide analog compounds |
| CN201410142432.6A Active CN103880699B (en) | 2014-04-10 | 2014-04-10 | Method for synthesizing imides compounds |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN104744290B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115960008A (en) * | 2021-10-09 | 2023-04-14 | 中国石油化工股份有限公司 | Synthesis method of imide derivative |
| WO2023056957A1 (en) * | 2021-10-09 | 2023-04-13 | 中国石油化工股份有限公司 | Working solution for producing hydrogen peroxide by means of anthraquinone method and solvent system thereof |
| CN115806502B (en) * | 2022-12-29 | 2024-02-23 | 杭州百凯生物医药有限公司 | Alpha-amidoketone derivative and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2966248B1 (en) * | 2010-10-18 | 2020-05-01 | Centre National De La Recherche Scientifique (Cnrs) | METHOD FOR FUNCTIONALIZING SURFACES FOR THE DETECTION OF ANALYTES |
| CN101985415B (en) * | 2010-11-11 | 2013-01-02 | 江南大学 | Preparation method of verbenol and verbenone through air oxidation of a-pinene at room temperature |
| CN102516138A (en) * | 2011-10-31 | 2012-06-27 | 成都理工大学 | N-aryl t-butyl sulfonamide, synthetic method and application thereof |
-
2014
- 2014-04-10 CN CN201510101921.1A patent/CN104744290B/en active Active
- 2014-04-10 CN CN201510101942.3A patent/CN104788337B/en active Active
- 2014-04-10 CN CN201510101939.1A patent/CN104788335B/en active Active
- 2014-04-10 CN CN201510101941.9A patent/CN104788336B/en active Active
- 2014-04-10 CN CN201410142432.6A patent/CN103880699B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104788335A (en) | 2015-07-22 |
| CN103880699B (en) | 2015-04-08 |
| CN103880699A (en) | 2014-06-25 |
| CN104788335B (en) | 2016-09-28 |
| CN104788336A (en) | 2015-07-22 |
| CN104744290A (en) | 2015-07-01 |
| CN104788336B (en) | 2016-11-30 |
| CN104788337A (en) | 2015-07-22 |
| CN104744290B (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111704582B (en) | Preparation method of Favipiravir and derivatives thereof | |
| CN104788337B (en) | The synthetic method of imide analog compounds | |
| CN106905125A (en) | A kind of method that ketone α alkyl of cobalt catalysis is combined to ketones derivant | |
| CN104725267B (en) | The synthetic method of imide analog compounds | |
| CN104725266B (en) | The synthetic method of imide analog compounds | |
| CN105175373B (en) | Synthetic method of aryl ketone coumarin derivative | |
| CN113072470B (en) | N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof | |
| CN108299384A (en) | Trifluoromethylthio transfering reagent compound and its synthetic method | |
| CN107915653A (en) | Catalysis ester and amine carry out the method that reaction prepares acid amides | |
| CN103880675B (en) | Improved catalyzed synthesis method for 1,4-dicarbonyl compound | |
| CN109265403B (en) | Synthesis method of benzimidazole and derivatives thereof | |
| CN107915694A (en) | 1 [2 (2,4 3,5-dimethylphenyl sulfydryl) phenyl] piperazine hydrochloride and preparation method thereof | |
| CN106905166B (en) | A method of synthesis secondary amine | |
| CN105330690A (en) | Synthetic method of drug intermediate aryl ketone phosphate ester compound | |
| CN109134338A (en) | Pyrrolidines tertiary amine is the alpha-aminonitriles compounds process for production thereof of substrate | |
| CN110003061A (en) | A kind of method of the hydrocarbon direct aminatin of methyl aromatic compound benzyl of iron catalysis | |
| CN105130983B (en) | A kind of synthetic method of medicine intermediate Pyrazolopyridine compound | |
| CN102093258A (en) | Aromatic diamidine compound and synthesis method thereof | |
| Achmatowicz et al. | The synthesis of l-proline derived hexaazamacrocyclic ligands of C3 symmetry via intramolecular methyl ester aminolysis | |
| CN100554269C (en) | A kind of method for preparing the triazolo pyrimidine compounds | |
| CN101024619B (en) | Method for synthesizing N-substituted O-bromobenzylacidamide | |
| CN107118214B (en) | A kind of synthetic method of compound | |
| CN110330446A (en) | A kind of preparation method of the unnatural amino acid of alkenyl containing γ or β alkenyl | |
| CN104892587B (en) | A kind of synthetic method of medicine intermediate triazole class compounds | |
| CN105153158B (en) | Synthesis method for medical intermediate nitrogen-containing heterocyclic fused derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170505 Address after: 226000 Jiangsu province Nantong City Jiuhua high tech Industrial Development Zone, Road No. 888 Patentee after: Jiangsu Deming New Material Co., Ltd. Address before: 325600 Zhejiang city of Wenzhou province Yueqing City Yuecheng town Fortunearia hole village Patentee before: Shen Jun |